CompletedPHASE1, PHASE2NCT04520321
A Phase 1/ Phase 2 Study of TTHX1114(NM141)
Studying Fuchs endothelial corneal dystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Trefoil Therapeutics, Inc.
- Principal Investigator
- Thomas M Tremblay, RN BSNTrefoil Therapeutics
- Intervention
- TTHX1114(NM141)(drug)
- Enrollment
- 22 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2021
Study locations (8)
- North Bay Eye Associates, Inc., Petaluma, California, United States
- Levenson Eye Associates, Inc, Jacksonville, Florida, United States
- Chicago Corneal Consultants, Hoffman Estates, Illinois, United States
- Price Vision Group, Indianapolis, Indiana, United States
- Tauber Eye Center, Kansas City, Missouri, United States
- Vance Thompson Vision - Omaha, Omaha, Nebraska, United States
- Alterman, Modi and Wolter, Poughkeepsie, New York, United States
- Vance Thompson Vision - Sioux Falls, Sioux Falls, South Dakota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04520321 on ClinicalTrials.gov